Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: What Glimmer Through Yonder Gloom Breaks?

Executive Summary

As Brexit-induced volatility continued to reverberate across the stock market last week, investment bank analysts started to downgrade companies by lowering their full-year earnings estimates. The prospects for second-quarter earnings season could have not have looked bleaker. Then paradoxically, at the end of the week, a clinical hold on a breakthrough biotechnology company product provided a glimmer of hope in the sector.

You may also be interested in...

Stockwatch: 2017, Year Of The Dog

News in the life sciences sector over the holiday period was peppered with clinical and regulatory failures at Acadia, Anthera, Opko and Cempra, and a drug pricing controversy from Biogen. Following underperformance in 2016 and with that sort of run-up, 2017 already looks likely to be another lost one.

Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Juno Therapeutics Inc. planned to win US FDA approval in 2017 for its chimeric antigen receptor T cell (CAR-T) cell therapy JCAR015, but the company has reached another significant milestone that may delay that goal: its Phase II ROCKET clinical trial in the treatment of adults with relapsed or refractory B cell acute lymphoblastic lymphoma (ALL) has been put on clinical hold due to three deaths.

Salix sinks as audit admission hurts M&A potential

Salix Pharmaceuticals lost 38.3% of its recently rising value – chopping more than $3bn from its market cap – after the stock market closed on 6 November following the immediate resignation of the company's chief financial officer and Salix's admission that an audit of its inventory levels is ongoing.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts